Neumora Therapeutics Initiates Phase 1 Study for Schizophrenia Drug NMRA-861

Neumora Therapeutics Inc. (NASDAQ:NMRA) is one of the best IPO stocks to buy according to Wall Street analysts. Earlier on July 9, Neumora Therapeutics initiated a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study for its drug candidate, called NMRA-861.

The study is being conducted in healthy adult participants and adults with stable schizophrenia. In preclinical studies, NMRA-861 demonstrated a strong pharmacological profile and was found to be safe and well-tolerated.

Neumora Therapeutics Initiates Phase 1 Study for Schizophrenia Drug NMRA-861

A close-up of a staff member counting pills in a pharmaceutical warehouse.

Neumora expects to report data from the Phase 1 SAD/MAD study in the first quarter of 2026. This data will include assessments of the drug’s safety, tolerability, and human pharmacokinetic data, which will confirm its potential for once-daily dosing and central nervous system penetration.

Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the US.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

This article is originally published at Insider Monkey.